I'm LongbridgeAI, I can summarize articles.RC Capital exited its investment in SPR Therapeutics following Medtronic's acquisition of the pain-management device maker. This transaction marked the sixth liquidity event for RC Capital’s Fund VI. SPR Therapeutics is known for its SPRINT platform, a minimally invasive non-opioid pain treatment system, supported by 291 patents and over 130 peer-reviewed publications.
- RC Capital exited its investment in SPR Therapeutics following Medtronic’s acquisition of the pain-management device maker. * The deal marked the sixth liquidity event for RC Capital’s Fund VI. * SPR Therapeutics expanded commercialization of its SPR Peripheral Nerve Stimulation System, a minimally invasive platform positioned as a non-opioid pain treatment. * The company reported 291 issued and pending patents, supported by more than 130 peer-reviewed publications on its SPRINT platform. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. RC Capital published the original content used to generate this news brief on September 15, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here